Stock SCOL SCANDION ONCOLOGY A/S
Add to a list
To use this feature you must be a member
Log inSign up

All News Scandion Oncology A/S

Equities

SCOL

DK0061031895

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
0.212 SEK -3.64% Intraday chart for Scandion Oncology A/S -26.90% -94.69%
May. 22 Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
May. 22 Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Scandion Oncology board member Michel Ducreux steps down, joins advisory board
AQ
SCANDION ONCOLOGY ANNOUNCES OUTCOME OF THE RIGHTS ISSUE
AQ
Scandion announces change of Certified Adviser to Vator Securities
AQ
SCANDION ONCOLOGY PUBLISHES PROSPECTUS RELATING TO THE RIGHTS ISSUE
AQ
Scandion Oncology Q1 2024 - Funding for CORIST part 3 extension
AQ
Transcript : Scandion Oncology A/S, Q1 2024 Earnings Call, May 22, 2024
Scandion Oncology – Interim Report Q1 2024
AQ
Scandion Oncology A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Invitation to Scandion Oncology webcast and conference call May 22, 2024
AQ
Transcript : Scandion Oncology A/S - Special Call
Scandion confirms positive final Phase Ib data from PANTAX trial with SCO-101
AQ
Scandion Confirms Positive Final Phase Ib Data from Pantax Trial with Sco-101
CI
Scandion Oncology Announces Results of Annual General Meeting and Constitution of the Board of Directors
AQ
Scandion Oncology to Host R&D Update May 15
AQ
Scandion Oncology – Notice convening the Annual General Meeting
AQ
Scandion Oncology reports promising updated Phase II CORIST data, including topline overall survival
AQ
Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival
CI
Scandion Oncology - Annual Report 2023
AQ
Scandion Oncology reports second confirmed partial response in the Phase IIa CORIST Part 3 trial
AQ
Scandion Oncology Reports Second Confirms Partial Response in the Phase IIa CORIST Part 3 Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SCOL Stock
  4. News Scandion Oncology A/S